Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Clinical trial NCT05353439 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05353439
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Extensive Stage Lung Small Cell Carcinoma Limited Stage Lung Small Cell Carcinoma Platinum-Resistant Lung Small Cell Carcinoma Platinum-Sensitive Lung Small Cell Carcinoma Recurrent Extensive Stage Lung Small Cell Carcinoma Recurrent Lung Small Cell Carcinoma

Start date: 2022-07-27
Primary completion: 2026-02-11
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.